MedTrace Logo

Primary Resistance in HIV Patients in Colombia

NCT03957369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 527

Last updated 2025-02-19

No results posted yet for this study

Summary

The investigators' main objective is to determine the prevalence of pre-treatment of resistance-associated mutations (RAMs) in a naïve and recently diagnosed HIV infection in 18 centers from 12 cities in Colombia. This evaluation will include the genotyping of all three enzymes, reverse transcriptase, protease, and integrase. This type of complete primary resistance profile has not yet been reported in Colombia and there is only scanty data regarding resistance-associated mutations to NRTIs, NNRTIs, and PIs in the country

Conditions

  • HIV Infection

Interventions

DIAGNOSTIC_TEST

HIV-1 plasma RNA Genotyping secuencing by Sanger technique

After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.

DIAGNOSTIC_TEST

HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique

After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Centro de Investigación en. Enfermedades Infecciosas, Mexico

    collaborator OTHER_GOV

  • Fundacion REVIVA, Red de VIH del Valle del Cauca

    lead NETWORK

Principal Investigators

  • ERNESTO MARTINEZ · Fundacion REVIVA, Red de VIH del Valle del Cauca

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2023-11-30
Completion
2024-04-01

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03957369 on ClinicalTrials.gov